Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors

J Labelled Comp Radiopharm. 2018 Mar;61(3):309-325. doi: 10.1002/jlcr.3581. Epub 2018 Jan 5.

Abstract

The neurotensin receptors are overexpressed in various tumor types, especially in highly progressive pancreatic tumors. As this cancer has a poor 5-year survival prognosis, there is an urgent need to improve early diagnosis and treatment strategies. This review article provides an overview of the latest developments in radiopharmaceuticals for neurotensin receptor-positive tumors, including peptidic and non-peptidic radiopharmaceuticals, not only for SPECT and PET but also for endoradiotherapy.

Keywords: NTS1; PET; SPECT; endoradiotherapy; neurotensin; neurotensin receptor; pancreatic tumor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Humans
  • Neurotensin / analogs & derivatives*
  • Pancreatic Neoplasms / diagnostic imaging*
  • Pancreatic Neoplasms / radiotherapy
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals / chemistry*
  • Radiopharmaceuticals / pharmacology
  • Radiopharmaceuticals / therapeutic use
  • Radiotherapy / methods
  • Receptors, Neurotensin / metabolism

Substances

  • Radiopharmaceuticals
  • Receptors, Neurotensin
  • Neurotensin